Usana Health Sciences (USNA) Cash & Equivalents (2010 - 2026)

Usana Health Sciences (USNA) has 17 years of Cash & Equivalents data on file, last reported at $162.8 million in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $162.8 million, down 9.39% year-over-year; the trailing twelve-month figure through Apr 2026 was $162.8 million (down 9.39% YoY), and the FY2026 annual result was $158.4 million, down 12.87% from the prior year.
• Cash & Equivalents rose to $162.8 million in Q2 2026 per USNA's latest filing, from $158.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $364.9 million in Q3 2024 and troughed at $145.3 million in Q3 2025.
• A 5-year average of $249.0 million and a median of $243.4 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents soared 30.3% in 2023, then slumped 60.17% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $288.4 million in 2022, then gained by 14.56% to $330.4 million in 2023, then sank by 44.99% to $181.8 million in 2024, then dropped by 20.04% to $145.3 million in 2025, then climbed by 11.97% to $162.8 million in 2026.
• Business Quant data shows USNA's Cash & Equivalents at $162.8 million in Q2 2026, $158.4 million in Q1 2026, and $145.3 million in Q3 2025.